Great Point Partners’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-675,000
| Closed | -$13.6M | – | 50 |
|
|
2026
Q1 | $13.6M | Sell |
675,000
-10,632
| -2% | -$171K | 3.12% | 11 |
|
|
2025
Q4 | $11.1M | Buy |
+685,632
| New | +$9.08M | 3.59% | 11 |
|
|
2025
Q3 | – | Sell |
-323,170
| Closed | -$3.65M | – | 35 |
|
|
2025
Q2 | $3.65M | Sell |
323,170
-691,197
| -68% | -$8.45M | 2.38% | 16 |
|
|
2025
Q1 | $11.7M | Sell |
1,014,367
-772,636
| -43% | -$7.89M | 6.2% | 2 |
|
|
2024
Q4 | $15.1M | Buy |
1,787,003
+487,500
| +38% | +$5.05M | 7.13% | 3 |
|
|
2024
Q3 | $15M | Sell |
1,299,503
-39,065
| -3% | -$491K | 4.43% | 7 |
|
|
2024
Q2 | $15.8M | Buy |
+1,338,568
| New | +$15.6M | 3.02% | 13 |
|
|
2023
Q2 | – | Sell |
-1,600,545
| Closed | -$12.6M | – | 46 |
|
|
2023
Q1 | $12.6M | Buy |
1,600,545
+544,744
| +52% | +$4.06M | 2.47% | 19 |
|
|
2022
Q4 | $7.14M | Sell |
1,055,801
-495,918
| -32% | -$2.66M | 1.4% | 25 |
|
|
2022
Q3 | $22.5M | Buy |
1,551,719
+21,719
| +1% | +$304K | 5.42% | 7 |
|
|
2022
Q2 | $15.1M | Buy |
1,530,000
+655,803
| +75% | +$7.23M | 3.61% | 11 |
|
|
2022
Q1 | $12.9M | Buy |
874,197
+462,260
| +112% | +$6.64M | 3.11% | 15 |
|
|
2021
Q4 | $5.45M | Buy |
+411,937
| New | +$6.56M | 1.21% | 28 |
|
Other funds holding KALV
Great Point Partners's KALV Position: Q2 2026 in Review
Great Point Partners sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 675,000 shares — an estimated $13.6M sold.
Great Point Partners first reported a position in KALV in Q4 2021 and held it in 13 quarters. The position peaked at $22.5M in Q3 2022. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Great Point Partners reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Great Point Partners sold 675,000 KalVista Pharmaceuticals shares in Q2 2026, an estimated $13.6M.
- Great Point Partners first reported a position in KalVista Pharmaceuticals in Q4 2021 and held it in 13 quarters.
- Great Point Partners's KalVista Pharmaceuticals position peaked at $22.5M in Q3 2022.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.